References
- Kyseloa, A., Stefek, M. and Bauer, V. (2004) Pharmaco-logical prevention of diabetic cataract. J. Diabetes Complicat. 18: 129-140 https://doi.org/10.1016/S1056-8727(03)00009-6
- Vinson, J. A. and Howard III, T. B. (1996) Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J. Nutr. Biochem. 7: 659-663 https://doi.org/10.1016/S0955-2863(96)00128-3
- Collins, J. B. and Corder, C. N. (1977) Aldose reductase and sorbitol dehydrogenase distribution in substrctures of normal and diabetic rats lens. Invest. Ophthamol. Visual Sci. 16: 242-243
- Dvonik, D., Gabbay, K. H. and Kinoshita, J. H. (1973) Polyol accumulation in galactosemic and diabetic rats. Science 182: 1146-1148 https://doi.org/10.1126/science.182.4117.1146
- Jesus Angel, de la F. and Sonia, M. (2003) Aldose reductase inhibitors from natural sources. Nat. Prod. Rep. 20: 243-251 https://doi.org/10.1039/b204709h
- Kawanishi, K., Ueda, H. and Moriyasu, M. (2003) Aldose reductase inhibitors from the nature. Current Medicinal Chemistry 10: 1353-1374 https://doi.org/10.2174/0929867033457304
- Lee, Y. M., Kim, N. H., Kim, J. M., Kim, Y. S., Jang, D. S., Kim, J. H., Bae, K. H. and Kim, J. S. (2008) Screening of Inhibitory Effect on Aldose Reductase of Korean Herbal Medicines and Preventive Effect of Catalpa bignonioides against Xylose-induced Lens Opacity (). Kor. J. Pharmacogn. 39: 165-173
- Dufrane, S. P., Malaisse, W. J. and Sener, A. (1984) A micromethod for the assay of aldose reductase, its application to pancreatic islets. Biochem. Med. 32: 99-105 https://doi.org/10.1016/0006-2944(84)90012-7
- Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Radall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275
- Kinoshita, J. H., Dvornik, D., Kraml, M. and Gabbay, K. H. (1968) The effect of an aldose reductase inhibitor on the galactose-exposed rabbit lens. Biochim. Biophys. Acta. 24: 472-475
- Kaul, D. L. and Ramarao, P. (2001) The role of aldose reductase inhibitors in diabetic complications: recent trends. Methods Find Exp. Clin. Pharmacol. 23: 465-475 https://doi.org/10.1358/mf.2001.23.8.662134
- Matsumoto, T., Ono, Y., Kurono, M., Kuromiya, A., Nakamura, K. and Bril, V. (2008) Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J. Pharmacol. Sci. 107: 231-237 https://doi.org/10.1254/jphs.08061FP
- Sun, W., Oates, P. J., Coutcher, J. B., Gerhardinger, C. and Lorenzi, M. (2006) A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55: 2757-2762 https://doi.org/10.2337/db06-0138
- Drel, V. R., Pacher, P., Ali, T. K., Shin, J., Julius, U., El-Remessy, A. B. and Obrosova, I. G. (2008) Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int. J. Mol. Med. 21: 667-676
- Hotta , N., Akanuma , Y., Kawamori , R., Matsuoka, K., Oka, Y., Shichiri , M., Toyota , T., Nakashima , M., Yoshimura, I., Sakamoto, N. and Shigeta, Y. (2006) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. Diabetes Care 29: 1538-1544 https://doi.org/10.2337/dc05-2370
- Constantino, L., Rastelli, G., Vianello, P., Cignarella, G. and Barlocco, D. (1999) Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Medical Research Reviews 19: 3-23 https://doi.org/10.1002/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.0.CO;2-7
- Ziegler, D. (2004) Polyneuropathy in the diabetic patient-update on pathogenesis and management. Nephrol. Dial. Transplant. 19: 2170-2175 https://doi.org/10.1093/ndt/gfh398
- Chalk, C., Benstead, T. J. and Moore, F. (2007) Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst. Rev. 4:CD004572
- Ono Pharmaceutical Co, Ltd. (2005) Kinedak (epalrestat) package insert. Chuo-ku, Osaka, Japan
- Ramirez, M. A. and Borja, N. L. (2008) Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy. 28: 646-655 https://doi.org/10.1592/phco.28.5.646
- Iso, K., Tada, H., Kuboki, K. and Inokuchi, T. (2001) Longterm effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in type 2 diabetic patients. J. Diabetes Complicat. 15: 241-244 https://doi.org/10.1016/S1056-8727(01)00160-X
- Yang, Y., Zhang, J. and Chen, Y. T. (2003) The extraction and isolation handbook of natural product constituents, 439. China Press of Traditional Chinese Medicine
- Kim, H. J and Lee, Y. S. (2005) Identification of new dicaffeoylquinic acids from Chrysanthemum morifolium and their antioxidant activities. Planta Med. 71: 871-876 https://doi.org/10.1055/s-2005-873115
- Huang, T. M., Na, M. K., Thuong, P. T., Su, N. D., Sok, D. E., Song, K. S., Seong, Y. H., and Bae, K. H. (2006) Antioxidant activity of caffeoyl quinic acid derivatives from the roots of Dipsacus asper Wall. J. Ethnopharmacol. 108: 188-192 https://doi.org/10.1016/j.jep.2006.04.029
- Xiang, T., Xiong, Q. B., Ketut, A., Tezuka, Y., Nagaoka, T. Wu, L. J. and Kadota, S. (2001) Studies on the hepatocyte protective activity and the structure-activity relationships of quinic acid and caffeic acid derivatives from the flower buds of Lonicera bournei. Planta Med. 67: 322-325 https://doi.org/10.1055/s-2001-14337
- Shahat, A. A., Nazif, N. M., Abousetta, L. M., Ibrahim, N. A., Cos, P., Miert, S. V., Pieters, L. and Vlietinck, A. J. (2005) Phytochemical investigation and antioxidant activity of Duranta repens. Phytother. Res. 19: 1071-1073 https://doi.org/10.1002/ptr.1766
- Wu, P. L., Lin, S. B., Huang, C. P. and Chiou, R. Y. Y. (2002) Antioxidative and cytotoxic compounds extracted from the Sap of Rhus Succedanea. J. Nat. Prod. 65: 1719-1721 https://doi.org/10.1021/np0201467
- Iqbal, K., Malik, A., Mukhtar, N., Anis, I., Khan, S. N. and Choudhary, M. I. (2004) a-Glucosidase inhibitory constituents from Duranta repens. Chem. Pharm. Bull. 52: 785-789 https://doi.org/10.1248/cpb.52.785
- Yang, J. H, Luo, S. D., Zhao, J. F., Wang, Y. S., Huang, R., Zhang, H. B. and Li, L. (2005) Three new highly oxygenated diterpenoids from Excoecaria cochinchinensis Lour. Helvetica Chimica Acta. 88: 968-973 https://doi.org/10.1002/hlca.200590090
- Giang, P. M., Son, P. T., Matsunami, K. and Otsuka, H. (2005) New megastigmane glucosides from Excoecaria cochinchinensis LOUR. var. cochinchinensis. Chem. Pharm. Bull. 53: 1600-1603 https://doi.org/10.1248/cpb.53.1600
- Do, T. L. (1991) Vietnamese Medicinal Plants and Herbal Remedies. Science and Technology, Hanoi, 555-556
- Kaou, A. M., Mahiou-Leddet, V., Hutter, S., Ainouddine, S., Hassani, S., Yahaya, I., Azas, N. and Ollivier, E. (2008) Antimalarial activity of crude extracts from nine African medicinal plants. J. Ethnopharmacol. 116: 74-83 https://doi.org/10.1016/j.jep.2007.11.001
- Muthaura, C. N., Rukunga, G. M., Chhabra, S. C., Omar, S. A., Guantai, A. N., Gathirwa, J. W., Tolo, F. M., Mwitari, P. G., Keter, L. K., Kirira, P. G., Kimani, C. W., Mungai, G. M. and Njagi, E. N. (2007) Antimalarial activity of some plants traditionally used in treatment of malaria in Kwale district of Kenya. J. Ethnopharmacol. 112: 545-551 https://doi.org/10.1016/j.jep.2007.04.018
- Zhang, H., Wang, X., Chen, F., Androulakis, X. M. and War-govich, M. J. (2007) Anticancer activity of limonoid from Khaya senegalensis. Phytother Res. 21: 731-734 https://doi.org/10.1002/ptr.2148
- Kayser, O. and Abreu, P. M. (2001) Antileishmania and immunostimulating activities of two dimeric proanthocyanidins from Khaya senegalensis. Pharm. Biol. 39: 284-288 https://doi.org/10.1076/phbi.39.4.284.5921
- Huang, K. C. and Williams, W. M. (1998) The Pharmacology of Chinese Herbs. 404, CRC Press
- Hisashi, M., Toshio, M., Iwao, T. and Masayuki, Y. (2002) Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem. Pharm. Bull. 50: 788-795 https://doi.org/10.1248/cpb.50.788